A commitment to research is fundamental to our mission at Biogen Idec; to create new standards of care for unmet medical needs, we must continually develop more effective ways to approach research. As with everything else we do, our approach to R&D is disciplined, focused and strategic.
At Biogen Idec, R&D is closely aligned with our business units. By applying our expertise in biologics and our growing capabilities in small-molecule drug discovery and development, we target specific medical needs where new or better treatments are needed.
Our R&D strategy is to discover and develop first-in-class molecules or best-in-class molecules that improve safety or efficacy for unmet medical needs. We look for discoveries that either break new ground in treatment or improve upon current therapies in meaningful ways.
Of course, a carefully constructed R&D strategy is meaningless without results. Through a combination of internal research, partnerships and acquisitions, we have a robust pipeline, including more than 20 products in Phase 2 clinical trials and beyond.
Research Facts
- 245 researchers
are developing 144 different compounds - 14,000 patients
were served by our access-to-medicines program in 2009
